Teva Pharmaceutical Industries Financial Ratios
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Teva Pharmaceutical Industries ratio analysis
Teva Pharmaceutical Industries earned a net margin of 8.2% in FY 2025, up from -9.9% a year earlier. Gross margin was 51.8% compared with a median of 47.8% over the prior 9 years. Return on equity reached 17.8%, meaning Teva Pharmaceutical Industries generated 0.18 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.23 versus 0.33 the year before, and the current ratio was 1.04. At the end of FY 2025, TEVA traded at 25.6 times earnings; across the 3 fiscal years shown, its year-end P/E ranged from 21.1 to 517.9, with a median of 25.6. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Teva Pharmaceutical Industries financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 25.58 | — | — | — | 21.08 | — | — | — | — | 517.86 |
| Price / sales | 2.05 | 1.45 | 0.74 | 0.68 | 0.56 | 0.63 | 0.59 | 0.97 | 0.88 | 0.00 |
| Price / book | 4.48 | 4.47 | 1.56 | 1.30 | 0.86 | 1.05 | 0.71 | 1.21 | 1.11 | 0.00 |
| Gross margin | 51.8% | 48.7% | 48.2% | 46.7% | 47.8% | 46.4% | 44.6% | 45.4% | 48.6% | 53.2% |
| Operating margin | 12.5% | -1.8% | 2.7% | -14.7% | 10.8% | -21.4% | -2.6% | -9.0% | -80.0% | 9.8% |
| Net margin | 8.2% | -9.9% | -3.5% | -16.4% | 2.6% | -24.0% | -5.9% | -11.8% | -74.4% | 1.5% |
| Free cash flow margin | 6.7% | 4.5% | 5.3% | 7.0% | 1.5% | 3.8% | 1.3% | 9.8% | 6.2% | 13.6% |
| Return on equity (ROE) | 17.8% | -30.5% | -7.4% | -31.3% | 4.1% | -39.8% | -7.2% | -14.6% | -93.7% | 1.0% |
| Return on assets (ROA) | 3.5% | -4.2% | -1.3% | -5.6% | 0.9% | -7.9% | -1.7% | -3.5% | -23.0% | 0.4% |
| Debt / equity | 0.23 | 0.33 | 0.22 | 0.27 | 0.14 | 0.32 | 0.17 | 0.15 | 1.87 | 1.07 |
| Current ratio | 1.04 | 0.98 | 1.02 | 1.05 | 1.14 | 0.99 | 0.98 | 0.96 | 0.86 | 0.93 |
| Revenue growth | 4.3% | 4.4% | 6.2% | -6.0% | -4.7% | -1.4% | -7.6% | -16.4% | -0.2% | 7.8% |
| EPS growth | — | — | — | -678.9% | — | — | — | — | -23,328.6% | -95.3% |